We first interrogated publicly available proteomics datasets from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) using the UALCAN portal37 and found that MBD2 expression was significantly upregulated in tissues of breast cancer and several other common types of cancer compared to the normal counterparts (Fig. 1a). Here, MBD2 is linked to breast carcinoma.